STERIS plc (NYSE:STE) Forecasted to Post Q3 2024 Earnings of $2.17 Per Share

STERIS plc (NYSE:STEFree Report) – Research analysts at KeyCorp issued their Q3 2024 EPS estimates for shares of STERIS in a research report issued on Monday, February 5th. KeyCorp analyst B. Fishbin expects that the medical equipment provider will post earnings per share of $2.17 for the quarter. KeyCorp has a “Overweight” rating and a $253.00 price target on the stock. The consensus estimate for STERIS’s current full-year earnings is $8.66 per share. KeyCorp also issued estimates for STERIS’s Q4 2024 earnings at $2.48 EPS, FY2024 earnings at $8.67 EPS and FY2025 earnings at $9.75 EPS.

STERIS (NYSE:STEGet Free Report) last released its quarterly earnings results on Wednesday, February 7th. The medical equipment provider reported $2.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.17 by $0.05. STERIS had a return on equity of 13.58% and a net margin of 10.52%. The business had revenue of $1.40 billion during the quarter, compared to the consensus estimate of $1.35 billion. During the same quarter in the previous year, the company posted $2.02 EPS. The business’s revenue was up 14.8% on a year-over-year basis.

STE has been the subject of a number of other research reports. TheStreet upgraded STERIS from a “c+” rating to a “b” rating in a report on Wednesday. JMP Securities reiterated a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research note on Thursday. Piper Sandler reduced their target price on STERIS from $220.00 to $215.00 and set a “neutral” rating for the company in a research note on Thursday, October 26th. Finally, Morgan Stanley dropped their price target on STERIS from $225.00 to $215.00 and set an “equal weight” rating on the stock in a research report on Monday, December 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $239.60.

Get Our Latest Analysis on STERIS

STERIS Trading Down 2.5 %

NYSE STE opened at $220.26 on Thursday. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.49 and a quick ratio of 1.55. STERIS has a 12 month low of $173.21 and a 12 month high of $254.00. The company has a market cap of $21.76 billion, a P/E ratio of 39.83 and a beta of 0.80. The company has a 50-day moving average of $215.75 and a 200-day moving average of $218.43.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 22nd. Investors of record on Friday, February 23rd will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, February 22nd. This represents a $2.08 annualized dividend and a yield of 0.94%. STERIS’s dividend payout ratio is currently 37.61%.

Hedge Funds Weigh In On STERIS

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Forum Financial Management LP grew its holdings in STERIS by 4.2% in the 2nd quarter. Forum Financial Management LP now owns 1,099 shares of the medical equipment provider’s stock valued at $247,000 after buying an additional 44 shares during the last quarter. First Hawaiian Bank grew its holdings in shares of STERIS by 0.4% during the 3rd quarter. First Hawaiian Bank now owns 12,490 shares of the medical equipment provider’s stock worth $2,741,000 after purchasing an additional 44 shares in the last quarter. Fortune Financial Advisors LLC grew its holdings in shares of STERIS by 0.7% during the 3rd quarter. Fortune Financial Advisors LLC now owns 7,022 shares of the medical equipment provider’s stock worth $1,541,000 after purchasing an additional 47 shares in the last quarter. Advisor OS LLC boosted its stake in STERIS by 3.8% in the 2nd quarter. Advisor OS LLC now owns 1,372 shares of the medical equipment provider’s stock valued at $309,000 after buying an additional 50 shares in the last quarter. Finally, Greenleaf Trust boosted its stake in STERIS by 2.8% in the 3rd quarter. Greenleaf Trust now owns 1,888 shares of the medical equipment provider’s stock valued at $414,000 after buying an additional 51 shares in the last quarter. Institutional investors and hedge funds own 92.91% of the company’s stock.

About STERIS

(Get Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Recommended Stories

Earnings History and Estimates for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.